Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun;12(3):146-148.
doi: 10.14740/cr1243. Epub 2021 May 14.

Myosin Modulators: The New Era of Medical Therapy for Systolic Heart Failure and Hypertrophic Cardiomyopathy

Dimitra Lekaditi  1 , Stefanos Sakellaropoulos  2
Affiliations
Review

Myosin Modulators: The New Era of Medical Therapy for Systolic Heart Failure and Hypertrophic Cardiomyopathy

Dimitra Lekaditi et al. Cardiol Res. 2021 Jun.

Abstract

A new uprising pharmacological treatment for systolic heart failure and hypertrophic cardiomyopathy demonstrates very promising results the last years. Myosin modulators have already been tested in numerous studies. Myosin inhibitor (mavacamten) and myosin stimulator, (omecamtiv mecarbil) exhibit their effect by improving clinical outcomes, as well as reducing morbidity and mortality. More studies are however required for further evaluation and particularly effect on sarcomeric level. Side effects of both pharmacological agents have been described and should always be close monitored. Cardiopulmonary exercise test has a pivotal role by means of assessing treatment efficacy.

Keywords: Heart failure; Hypertrophic cardiomyopathy; Myosin inhibitor; Myosin stimulator.

PubMed Disclaimer

Conflict of interest statement

None to declare.

Similar articles

See all similar articles

Cited by

References

    1. Tsukamoto O. Direct sarcomere modulators are promising new treatments for cardiomyopathies. Int J Mol Sci. 2019;21(1):226. doi: 10.3390/ijms21010226. - DOI - PMC - PubMed
    1. Fifer MA, Vlahakes GJ. Management of symptoms in hypertrophic cardiomyopathy. Circulation. 2008;117(3):429–439. doi: 10.1161/CIRCULATIONAHA.107.694158. - DOI - PubMed
    1. Sakellaropoulos S, Svab S, Mohammed M, Dimitra L, Mitsis A. The role of mitral valve in hypertrophic obstructive cardiomyopathy: an updated review. Curr Probl Cardiol. 2021;46(3):100641. doi: 10.1016/j.cpcardiol.2020.100641. - DOI - PubMed
    1. Green EM, Wakimoto H, Anderson RL, Evanchik MJ, Gorham JM, Harrison BC, Henze M. et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science. 2016;351(6273):617–621. doi: 10.1126/science.aad3456. - DOI - PMC - PubMed
    1. Kawas RF, Anderson RL, Ingle SRB, Song Y, Sran AS, Rodriguez HM. A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle. J Biol Chem. 2017;292(40):16571–16577. doi: 10.1074/jbc.M117.776815. - DOI - PMC - PubMed

LinkOut - more resources